RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, Any thoughts on what the following assets, partnered singly, might realistically bring Cortex in the July/August timeframe? (just looking for ballpark figures) -

1) RD partnership - including IV CX-717, and the IV prodrug CX-1942 (note - the non-prodrug version of CX-1942 could also be used by the partner in its oral form). CX-1739 is excluded from this deal.

2) ADHD related partnership - including CX-1739, plus a backup, or alternately, include 2 preclinical low impacts but not CX-1739. Partnership could be for ex-US rights, or alternately, for all global rights.

3) High impacts related partnership - includes the lead compound CX-1846, plus a backup, or alternately, a deal for the whole high impact platform.

4) RD as in #1 above, but also including SA rights (without full SA trial data).


Other ideas -


5) A licensing deal with Schering/Merck for several of Cortex's new generation preclinical low impacts. Alternately, a deal including CX-1739, plus a preclinical backup.

6) Monetize the future milestone/royalty stream from Schering's Schizo/Depression properties.

7) Any other money raising ideas you may have.


Thanks.